Purpose:

We evaluated the relationship between isocitrate dehydrogenase 1 (IDH1) mutation status and metabolic imaging in patients with nonenhancing supratentorial diffuse gliomas using ¹¹C-methionine positron emission tomography (¹¹C-MET PET).

Materials and Methods:

Between June 2012 and November 2017, we enrolled 86 (38 women and 48 men; mean age, 41.9 ± 13.1 years [range, 8-67 years]) patients with newly diagnosed supratentorial diffuse gliomas. All patients underwent preoperative ¹¹C-MET PET. Tumor samples were obtained and immunohistochemically analyzed for IDH1 mutation status.

Results:

The mutant and wild-type IDH1 diffuse gliomas had significantly different mean maximum standardized uptake value values (2.73 [95% confidence interval, CI: 2.32-3.16] vs 3.85 [95% CI: 3.22-4.51], respectively; P = .004) and mean tumor-to-background ratio (1.90 [95% CI: 1.65-2.16] vs 2.59 [95% CI: 2.17-3.04], respectively; P = .007).

Conclusions:

¹¹C-methionine PET can noninvasively evaluate the IDH1 mutation status of patients with nonenhancing supratentorial diffuse gliomas.

中文翻译：

---

IDH1突变状态与代谢性影像学在非增强性幕上弥漫性胶质瘤之间的关系：¹¹ C-MET PET研究

目的：

我们使用¹¹ C-蛋氨酸正电子发射断层显像（¹¹ C-MET PET）评估了非增强性幕上弥漫性胶质瘤患者的异柠檬酸脱氢酶1（IDH1）突变状态与代谢成像之间的关系。

材料和方法：

在2012年6月至2017年11月之间，我们招募了86例新诊断为幕上弥漫性神经胶质瘤的患者（38例女性和48例男性；平均年龄41.9±13.1岁[范围，8-67岁]。所有患者均接受术前¹¹ C-MET PET检查。获得肿瘤样品并免疫组织化学分析IDH1突变状态。

结果：

突变型和野生型IDH1弥漫性神经胶质瘤的平均最大标准化摄取值显着不同（分别为2.73 [95％置信区间，CI：2.32-3.16]与3.85 [95％CI：3.22-4.51]；P = .004 ）和平均肿瘤与背景的比率（分别为1.90 [95％CI：1.65-2.16]与2.59 [95％CI：2.17-3.04]；P = .007）。

结论：

¹¹ C-蛋氨酸PET可以无创地评估幕上弥漫性胶质瘤患者IDH1突变状态。